Arvinas (ARVN) Enterprise Value (2018 - 2026)
Arvinas (ARVN) posted quarterly Enterprise Value of -$614.9 million for Q1 2026, up 35.57% year-over-year from -$453.6 million in Q1 2025, and up 10.29% quarter-over-quarter from -$685.4 million in Q4 2025.
Analysis
Arvinas (ARVN) Enterprise Value (2018 - 2026) Analysis & Trends
Arvinas' Enterprise Value history runs 10 years deep, the most recent figure standing at -$614.9 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 35.57% year-over-year to -$614.9 million; the TTM figure through Mar 2026 stood at -$614.9 million (up 35.57% YoY), while the FY2025 annual figure was -$685.4 million, up 34.06% from the prior year.
- Enterprise Value for Q1 2026 stood at -$614.9 million, up from -$685.4 million in the prior quarter.
- The five-year high for Enterprise Value was -$66.8 million in Q1 2022, with the low at -$1.2 billion in Q1 2024.
- The 5-year median for Enterprise Value is -$160.3 million (2024), against an average of -$436.2 million.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value surged 91.06% in 2022, then sank 824.41% in 2025.
- Arvinas' Enterprise Value stood at -$86.8 million in 2022, then sank by 265.44% to -$317.2 million in 2023, then slumped by 227.68% to -$1.0 billion in 2024, then surged by 34.06% to -$685.4 million in 2025, then grew by 10.29% to -$614.9 million in 2026.
- Business Quant data shows ARVN's Enterprise Value at -$614.9 million in Q1 2026, -$685.4 million in Q4 2025, and -$787.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.26 Mn |
| Mar 31, 2026 | 68.80 Mn |
| Dec 31, 2025 | 67.71 Mn |
| Sep 30, 2025 | -184.38 Mn |
| Jun 30, 2025 | -322.45 Mn |
| Mar 31, 2025 | -441.84 Mn |
| Dec 31, 2024 | 279.50 Mn |
| Sep 30, 2024 | 570.48 Mn |
| Jun 30, 2024 | 597.43 Mn |
| Mar 31, 2024 | 1.65 Bn |
| Dec 31, 2023 | 1.02 Bn |
| Sep 30, 2023 | 961.00 Mn |
| Jun 30, 2023 | 1.23 Bn |
| Mar 31, 2023 | 1.32 Bn |
| Dec 31, 2022 | 1.73 Bn |
| Sep 30, 2022 | 2.23 Bn |
| Jun 30, 2022 | 2.14 Bn |
| Mar 31, 2022 | 3.51 Bn |
| Dec 31, 2021 | 4.24 Bn |
| Sep 30, 2021 | 2.79 Bn |